• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克与奥妥珠单抗治疗慢性淋巴细胞白血病
Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.
2
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
3
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.阿卡替尼、维奈托克和奥滨尤妥珠单抗作为慢性淋巴细胞白血病的一线治疗：一项单臂、开放标签、2 期研究。
Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14.
4
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.苯达莫司汀后继奥滨尤妥珠单抗和维奈克拉治疗慢性淋巴细胞白血病（CLL2-BAG）：多中心、开放标签、2 期试验的主要终点分析。
Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.
5
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
6
Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.维奈托克联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病。
Blood. 2019 Nov 14;134(20):1691-1696. doi: 10.1182/blood.2019001750.
7
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Venetoclax-Obinutuzumab 治疗初治及复发/难治性慢性淋巴细胞白血病的 1b 期临床研究。
Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.
8
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.阿替利珠单抗、维奈托克和奥滨尤妥珠单抗联合治疗Richter 转化弥漫性大 B 细胞淋巴瘤（MOLTO）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2024 Oct;25(10):1298-1309. doi: 10.1016/S1470-2045(24)00396-6. Epub 2024 Sep 10.
9
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.维奈托克联合奥滨尤妥珠单抗治疗复杂核型慢性淋巴细胞白血病患者疗效显著。
Blood. 2020 Mar 12;135(11):866-870. doi: 10.1182/blood.2019003451.
10
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.奥滨尤妥珠单抗、伊布替尼和维奈托克治疗复发/难治性慢性淋巴细胞白血病的 1b 期研究。
Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15.

引用本文的文献

1
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.慢性淋巴细胞白血病：2025年流行病学、发病机制、诊断与治疗最新进展
Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28.
2
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.BCL-2抑制剂与免疫疗法联合应用：血液系统恶性肿瘤的一种有前景的治疗策略。
Discov Oncol. 2024 Jul 26;15(1):311. doi: 10.1007/s12672-024-01161-3.
3
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.推进慢性淋巴细胞白血病的嵌合抗原受体T细胞疗法：探索耐药机制及克服这些机制的创新策略。
Cancer Drug Resist. 2024 May 14;7:18. doi: 10.20517/cdr.2023.100. eCollection 2024.
4
The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When.虚弱评估与慢性淋巴细胞白血病的五个“W”：何人、何事、何地、为何、何时。
Cancers (Basel). 2023 Sep 2;15(17):4391. doi: 10.3390/cancers15174391.
5
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.加拿大维奈托克和奥妥珠单抗作为慢性淋巴细胞白血病一线治疗方案的概率成本效益分析
Pharmacoecon Open. 2023 Mar;7(2):199-216. doi: 10.1007/s41669-022-00375-x. Epub 2022 Nov 5.
6
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.可测量残留病在预测 CLL 患者接受 BCR 和 BCL2 靶向治疗的治疗结果中的作用。
Leuk Lymphoma. 2022 Dec;63(12):2765-2784. doi: 10.1080/10428194.2022.2098291. Epub 2022 Aug 19.
7
Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?慢性淋巴细胞白血病中新型药物的联合应用：是否大于各部分之和？
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000197. eCollection 2019 Jun.
8
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.维奈托克联合低剂量阿糖胞苷或去甲基化药物作为不适合强化化疗的未经治疗的急性髓系白血病患者的诱导化疗：系统评价和荟萃分析。
Clin Exp Med. 2023 Jun;23(2):219-227. doi: 10.1007/s10238-021-00784-y. Epub 2022 Jan 23.
9
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.降解致死：泛素-蛋白酶体系统对细胞凋亡的调控。
Cells. 2021 Dec 8;10(12):3465. doi: 10.3390/cells10123465.
10
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.维奈托克在BCL2阳性复发/难治性外周T细胞淋巴瘤中显示出低治疗活性：意大利淋巴瘤基金会的一项2期研究
Front Oncol. 2021 Dec 6;11:789891. doi: 10.3389/fonc.2021.789891. eCollection 2021.

本文引用的文献

1
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病：一项1b期研究
Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
2
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.微小残留病灶评估改善慢性淋巴细胞白血病（CLL）患者达部分缓解患者的预后预测：德国 CLL 研究组两项 III 期研究的综合分析。
J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.
3
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
4
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
5
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.奥妥珠单抗单药治疗有症状的初治慢性淋巴细胞白血病的随机2期研究。
Blood. 2016 Jan 7;127(1):79-86. doi: 10.1182/blood-2015-03-634394. Epub 2015 Oct 15.
6
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
7
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.ABT-199，一种强效和选择性的 BCL-2 抑制剂，在发挥抗肿瘤活性的同时不影响血小板。
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
8
Therapy of elderly/comorbid patients with chronic lymphocytic leukemia.老年/合并症慢性淋巴细胞白血病患者的治疗。
Curr Pharm Des. 2012;18(23):3399-405. doi: 10.2174/138161212801227096.
9
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.微小残留病灶定量是慢性淋巴细胞白血病无进展和总生存的独立预测因子：来自随机 GCLLSG CLL8 试验的多变量分析。
J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

作者信息

Fischer Kirsten, Al-Sawaf Othman, Fink Anna-Maria, Dixon Mark, Bahlo Jasmin, Warburton Simon, Kipps Thomas J, Weinkove Robert, Robinson Sue, Seiler Till, Opat Stephen, Owen Carolyn, López Javier, Humphrey Kathryn, Humerickhouse Rod, Tausch Eugen, Frenzel Lukas, Eichhorst Barbara, Wendtner Clemens-M, Stilgenbauer Stephan, Langerak Anton W, van Dongen Jacque J M, Böttcher Sebastian, Ritgen Matthias, Goede Valentin, Mobasher Mehrdad, Hallek Michael

机构信息

Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.

F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom.

出版信息

Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21.

DOI:10.1182/blood-2017-01-761973
PMID:28325865
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5437733/
Abstract
摘要